|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
Genomic Health Literacy in Treatment Decision-Making for Prostate Cancer
|
| Elisabeth Heath, MD, FACP |
| Elisabeth Heath joins Alicia Morgans in a discussion on a patient-centered approach to discussing genetic and genomic testing for prostate cancer. |
|
|
|
|
|
|
|
|
|
|
|
|
The Risk of Prostate Cancer in Men with Inherited Germline TP53 Variants
|
|
Kara N. Maxwell, MD, Ph.D.
|
| In this discussion between Kara Maxwell and Alicia Morgans, Dr. Maxwell highlights the role of TP53 in cancer and understanding the Li-Fraumeni syndrome.
|
|
|
|
|
|
|
|
|
|
|
|
|
Genetic and Genomic Testing in Prostate Cancer
|
|
Emmanuel Antonarakis, MD
|
| At the 2022 Large Urology Group Practice Association (LUGPA) annual meeting, Emmanuel Antonarakis presented on Genetic and Genomic Testing in Prostate Cancer.
|
|
|
|
|
|
|
|
|
|
|
|
|
Incorporating Molecular Testing into Clinical Practice for Prostate Cancer
|
Elena Castro, MD and Colin C. Pritchard, MD, Ph.D.
Colin Pritchard and Elena Castro join Alicia Morgans in a conversation on incorporating molecular testing into our treatment paradigms for men with prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
| Optimizing Management of Localized Prostate Cancer: Combined Modality Therapy in Localized Disease
|
| Mary-Ellen Taplin, MD
|
| The 2022 GU ASCO Annual meeting included a session on the optimization management of localized prostate cancer, specifically looking at artificial intelligence (AI), active surveillance, and intervention, featuring a presentation by Dr. Mary-Ellen Taplin discussing combined modality therapy in localized prostate cancer.
|
|
|
|
|
|
| Lifetime Risk of Prostate Cancer Death Among High-Risk Germline Mutation Carriers |
| Roderick Clark, MD |
| Roderick Clark discusses the lifetime risk of prostate cancer death among high-risk germline mutation carriers. The objective of this study was to estimate the prostate cancer-specific mortality burden among individuals carrying high-risk germline mutations. This is the first study to estimate lifetime risk of metastatic disease and death among carriers with high-risk mutations. |
|
|
|
|
|
|
|
|
|
|
| Factors Associated With Gene Mutation Testing in United States Veterans With Metastatic Castration-Resistant Prostate Cancer
|
| Anna Hung, Ph.D.
|
| In this study, Dr. Hung utilized natural language processing (NLP) to search the Veterans Affairs Healthcare system database for patients with mCRPC, analyze rates of gene mutation testing in these patients, and determine factors associated with testing.
|
|
|
|
|
|
| PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
|
| Channing Judith Paller, MD
|
| A substantial minority of patients with prostate cancer have germline mutations in genes involved in DNA damage repair. Based on the prevalence of these alterations in advanced disease and the potential therapeutic benefit of targeting germline DNA damage repair vulnerabilities, treatment guidelines recommend genetic testing in high-risk localized, node positive, and metastatic disease.
|
|
|
|
|
|
Germline DNA Damage Repair Alterations in Patients with Localized Prostate Cancer Treated with Neoadjuvant Androgen Deprivation Therapy - Expert Commentary
|
| Bishoy M. Faltas, MD
|
| Germline DNA damage repair (gDDR) alterations are common in men with prostate cancer (PCa). Men with PCa and gDDR alterations showed poor clinical outcomes. It is unclear if men with high-risk PCa and gDDR alterations would respond differently to neoadjuvant androgen deprivation therapy (ADT) than men without gDDR alterations. |
|
|
|
|
|
|
